Oncotelic Therapeutics, Inc. (OTC:OTLC)
| Market Cap | 9.15M-79.9% |
| Revenue (ttm) | 250.00K |
| Net Income | 247.50M+6403.6% |
| EPS | 0.59+6144.3% |
| Shares Out | 457.51M |
| PE Ratio | 0.03 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 175,692 |
| Open | 0.02 |
| Previous Close | 0.02 |
| Day's Range | 0.02 - 0.03 |
| 52-Week Range | 0.01 - 0.11 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 18, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About OTLC
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Nov 18, 2026Earnings report
Ask Barron about OTLC
$OTLC stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in OTLC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OTLC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OTLC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New OTLC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OTLC from public contracts
Source: USAspending.gov
OTLC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from OTLC’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 100 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 60.1